Merck and Moderna have announced promising results from a clinical trial testing mRNA-4157 (V940), an investigational individualized neoantigen therapy, in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy. The trial, which was presented at the ASCO24 conference, focused on patients with high-risk stage III/IV melanoma. The combined treatment demonstrated sustained improvement in recurrence-free survival and distant metastasis-free survival over a 3-year period. This advancement is part of Merck's ongoing efforts to enhance its oncology pipeline.
Moderna and Merck announced promising results from a clinical trial testing a combined treatment of an mRNA vaccine and immunotherapy for skin cancer. https://t.co/FJUxpcxUkl
📢@moderna_tx and @Merck announce 3-year data for mRNA-4157 (V940) in combination with KEYTRUDA(R) (pembrolizumab) in study of patients with high-risk stage III/IV melanoma. #FlagshipFounded https://t.co/buE0IWcv9H
Moderna and @Merck today announced that mRNA-4157 (V940), an investigational individualized neoantigen therapy, in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, demonstrated sustained improvement in recurrence-free survival and distant metastasis-free survival compared… https://t.co/RnA2s2IIru
We’re pleased to share late-breaking data with @moderna_tx at #ASCO24 for our investigational individualized neoantigen therapy in combination with immunotherapy for #melanoma, as we continue to advance our oncology pipeline. Learn more here: https://t.co/7Ab7oXwYg7 https://t.co/x1okg7GLfu
#News for #Investors and #Media: We’re pleased to share the latest research from a trial evaluating our immuno-oncology therapy at ASCO24. Learn more: https://t.co/dFSla5ff38 https://t.co/UfVBoth4su